# GeneCentric Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genecentric-therapeutics

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.genecentric.com
- Total disclosed funding: $15M
- Latest round: Series C (Jun 4, 2025)
- Investors on record: 4

## About

GeneCentric Therapeutics, Inc. is a biotechnology firm focused on advancing precision oncology through innovative liquid biopsy technology that integrates gene expression analysis with circulating tumor DNA sequencing. Founded in 2011 and headquartered in Durham, North Carolina, GeneCentric Therapeutics, Inc. specializes in developing technologies for cancer diagnostics. In June 2025, GeneCentric Therapeutics, Inc. raised USD 8 million in series C funding led by returning investor Hatteras Venture Partners, with participation from other returning investors IAG Capital Partners, Alexandria Venture Investments, and Laboratory Corporation of America Holdings. GeneCentric specializes in advanced liquid biopsy technology that combines gene expression analysis with standard circulating tumor DNA (ctDNA) sequencing. Their flagship product, the ExpressCT™ technology, is integrated within the GenomicsNext™ platform, enabling precise detection of DNA alterations and gene expression, thus providing a comprehensive solution for precision cancer treatment. GeneCentric's offerings cater to biopharmaceutical companies, research institutions, and commercial laboratories, focusing on unmet medical needs in cancer genomic profiling across North America and Europe.GeneCentric generates revenue through partnerships and direct transactions with clients in the biopharma and research sectors. Their revenue model includes collaborations and licensing agreements that grant clients access to proprietary technologies such as the ExpressCT™ platform and GenomicsNext™ services. These agreements often involve service contracts for advanced genomic profiling and biomarker analysis, supporting innovative cancer treatment research. The company will use the June 2025 funding to support the commercialization of GenomicsNext and for further development.

## Funding rounds

- Series C, Jun 4, 2025, $2M — Alexandria Venture Investments, Hatteras Venture Partners, Laboratory Corporation of America Holdings, IAG Capital Partners
- Series B, Nov 8, 2021, $7.5M — Alexandria Venture Investments, Hatteras Venture Partners, Laboratory Corporation of America Holdings, IAG Capital Partners
- Series A, Jun 1, 2014, $2.5M — Hatteras Venture Partners, Laboratory Corporation of America Holdings
- Series A, Jun 26, 2013, $2.5M — Hatteras Venture Partners
- Seed, Sep 20, 2011, $0.3M — Hatteras Venture Partners

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Seed, Series A, Series B, Series C
- Laboratory Corporation of America Holdings — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Series B, Series C